Crossmark

Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access

Crossref DOI link: https://doi.org/10.1186/s12913-026-14094-0

Published Online: 2026-01-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lochid-amnuay, Surasit

Kongsakon, Ronnachai
License Information

Text and Data Mining valid from 2026-01-29

Version of Record valid from 2026-02-20
More Information

Article History

Received: 11 August 2025

Accepted: 20 January 2026

First Online: 29 January 2026

Declarations

:

: Not applicable. This study used secondary data from published sources and national databases; no human participants were directly involved.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below